BioVaxys Technology Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul '25 Jul 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020
Selling, General & Admin	4.2	2.82	2.12	2.34	4.12	0.42
Research & Development	0.03	0	0.13	0.96	0.73	0.24
Operating Expenses	4.64	3.12	2.4	3.8	5.98	1.01
Operating Income	-4.64	-3.12	-2.4	-3.8	-5.98	-1.01
Interest & Investment Income	-	-	-	-	0	0
Currency Exchange Gain (Loss)	-0.05	-0	-0.03	-0.02	-0.02	-0
Other Non Operating Income (Expenses)	-0.19	-0.17	-4.03	-0.26	-0.46	-0.09
EBT Excluding Unusual Items	-4.88	-3.3	-6.46	-4.08	-6.46	-1.1
Asset Writedown	-1.29	-1.29	-1.45	-7.4	-	-
Other Unusual Items	0.2	0.63	0.21	-0.25	-	-
Pretax Income	-5.97	-3.95	-7.69	-11.73	-6.46	-1.1
Earnings From Continuing Operations	-5.97	-3.95	-7.69	-11.73	-6.46	-1.1
Earnings From Discontinued Operations	-	-	-	-	-	-0.07
Net Income	-5.97	-3.95	-7.69	-11.73	-6.46	-1.17
Net Income to Common	-5.97	-3.95	-7.69	-11.73	-6.46	-1.17
Shares Outstanding (Basic)	28	20	13	10	8	3
Shares Outstanding (Diluted)	28	20	13	10	8	3
Shares Change (YoY)	61.26%	45.90%	36.63%	18.39%	193.97%	171.65%
EPS (Basic)	-0.22	-0.20	-0.57	-1.19	-0.78	-0.42
EPS (Diluted)	-0.22	-0.20	-0.57	-1.19	-0.78	-0.42
EBIT	-4.64	-3.12	-2.4	-3.8	-5.98	-1.01
Advertising Expenses	-	0.42	-	0.17	1.72	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.